← Back to Search

Apoptosis Inducer

BAY2666605 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 + 14 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new substance called BAY2666605 for adults with advanced cancers that don't respond to current treatments. BAY2666605 helps form a protein complex that makes cancer cells die. The study will see how the drug moves through the body, find the best dose, and check its safety and effectiveness.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 + 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 + 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of TEAEs including TESAEs
RP2D of BAY2666605
The incidence of DLTs at each dose level in the Dose Escalation part of the study
Secondary study objectives
DCR
DOR
ORR
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose expansion of BAY2666605Experimental Treatment1 Intervention
Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
Group II: Dose escalation of BAY2666605Experimental Treatment1 Intervention
Approximately 7 or 8 dose levels are planned.

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,274 Previous Clinical Trials
25,532,376 Total Patients Enrolled
~1 spots leftby Nov 2025